Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier:
NCT00457314
First received: April 5, 2007
Last updated: May 18, 2009
Last verified: May 2009

April 5, 2007
May 18, 2009
June 2007
June 2012   (final data collection date for primary outcome measure)
  • Changes in wild-type (normal), mutant, and total mitochondrial DNA copy number [ Time Frame: Measured at Week 26 ] [ Designated as safety issue: No ]
  • Physiological measure of oxidative metabolism [ Time Frame: Measured at Week 26 ] [ Designated as safety issue: No ]
  • Changes in wild-type (normal), mutant, and total mitochondrial DNA copy number measured at Week 26
  • physiological measure of oxidative metabolism measured at Week 26
Complete list of historical versions of study NCT00457314 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease
Exercise Training and Deconditions: Implications for Therapy in Mitochondrial Myopathy

Mitochondrial myopathies include various inherited diseases that are caused by damage to the mitochondria, energy-producing structures that fuel the body's processes. The main symptoms are muscle weakness, reduced muscle mass, and difficulty with exercising. The purpose of this study is to determine the effects of exercise training versus inactivity on mitochondrial function in muscle and muscle performance in people with mitochondrial myopathies.

Mitochondrial myopathies are caused by mutant mitochondrial DNA, genetic defects in parts of the mitochondrial DNA. These defects can include missing or deleted DNA that typically codes for certain proteins involved in energy production. These mutations cause individual mitochondria and the body on a whole to produce energy less efficiently. Because muscle cells require extensive energy to function properly, they are particularly impaired by mitochondrial dysfunction. The onset of most mitochondrial myopathies occurs before the age of 20. Initially a person may experience muscle weakness and fatigue during physical activity. Other symptoms may include limited eye mobility, heart arrhythmias, slurred speech, swallowing difficulties, and impaired movement.

There is no cure yet for mitochondrial myopathies, nor is there any adequate treatment to stall disease progression. Exercise, known to boost the production and function of mitochondria in healthy people, may reduce symptoms in people with mitochondrial myopathies by increasing the number and function of normal mitochondria in an individual muscle cell. The purpose of this study is to determine the effects of exercise training versus inactivity on the expression of normal and mutant mitochondrial DNA and on mitochondrial production within muscle cells in people with mitochondrial myopathies. The study will also assess how cell function, physical endurance, heart function, and quality of life are affected by exercise training and inactivity.

Participants in this 2-year study will first undergo physiological exercise testing, magnetic resonance imaging (MRI) of heart and skeletal muscles, a needle biopsy of muscle, and a questionnaire on quality of life. Participants will then be randomly assigned to partake in regular exercise training or no training for 6 months. After 6 months, all participants will undergo repeat testing of initial evaluations. Participants who had been in the exercising group will then switch to no exercise training for 6 months, and participants who had been in the non-exercising group will switch to regular exercise training for 6 months. The second 6-month period will also be followed by repeat testing of initial evaluations. Participants will then be encouraged to continue exercise training for an additional 1 year, with retesting at the end of the second year. Each of the four evaluations will take about 15 hours over 5 days.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Mitochondrial Myopathy
Behavioral: Exercise
Regular exercise training
  • Experimental: 1
    Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
    Intervention: Behavioral: Exercise
  • Experimental: 2
    Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
    Intervention: Behavioral: Exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of mitochondrial myopathy
  • Single-large scale deletions of mitochondrial DNA
  • Point mutations in mitochondrial DNA

Exclusion Criteria:

  • Symptoms or electrocardiogram-generated signs of coronary artery disease
  • Symptoms of congestive heart failure; peripheral vascular disease; or lung, kidney, or liver disease
  • History of alcohol or substance abuse
  • Metal implants or related devices that contraindicate MRI
  • Current use of or require any medications that have significant systemic cardiovascular effects
  • Diabetes
  • Obesity (body mass index [BMI] greater than 30)
  • Resting systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg at three different times
Both
18 Years to 65 Years
No
Contact: Ronald Haller, MD 214-345-4621 rhaller2@earthlink.net
Contact: Marta Newny 214-345-4655 martanewby@texshealth.org
United States
 
NCT00457314
R01 AR050597, 1 R01 AR050597-01A1
Yes
Ronald Haller, Universit y of Texas Southwestern Medical School
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not Provided
Principal Investigator: Ronald Haller, MD University of Texas Southwestern Medical Center
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP